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Abstract  
Background: Sympathetic tone is one of the main determinants of blood pressure 
(BP) variability and treatment-resistant hypertension (rHT).  The aim of our study 
was to assess changes in BP variability after renal (RDN). Additionally, on an ex-
ploratory basis, we investigated whether baseline BP variability predicted the BP 
changes after RDN.   
Methods: We analyzed 24-h BP recordings obtained at baseline and 6 months 
after RDN in 167 rHT patients (40 % women; age, 56.7 years; mean 24-h BP, 
152/90 mmHg) recruited at 11 expert centers. Blood pressure variability was as-
sessed by weighted standard deviation (SDiw), average real variability (ARV), coef-
ficient of variation (CV) and variability independent of the mean (VIM).  
Results: Mean office and 24-h BP fell by 15.4/6.6 mmHg and 5.5/3.7 mmHg, re-
spectively (P<0.001). In multivariable-adjusted analyses, systolic /diastolic SDiw 
and VIM for 24-h systolic/diastolic BP decreased by 1.16/0.63 mmHg (P≤ 0.01) and 
0.85/0.43 mmHg (P≤ 0.05), respectively, whereas no significant changes in ARV or 
CV occurred.  Furthermore, baseline SDiw (P=0.0006), ARV (P=0.012) and VIM 
(P=0.04) predicted the decrease in 24-h diastolic - but not 24-h systolic - BP after 
RDN.  
Conclusions: RDN was associated with a decrease in BP variability independent of 
the BP level, suggesting that responders may derive benefits from the reduction in 
BP variability as well. Furthermore, baseline diastolic BP variability estimates signif-
icantly correlated with mean diastolic BP decrease after RDN. If confirmed in 
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younger patients with less arterial damage, in the absence of the confounding effect 
of drugs and drug adherence, baseline BP variability may prove a good predictor of 
BP response to RDN. 
 
Keywords:  renal denervation  resistant hypertension  blood pressure variabil-
ity   ambulatory blood pressure measurement 
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Condensed abstract 
We analysed different blood pressure variability estimates in 167 patients with drug-
resistant hypertension recruited in 11 European expert centres from the ENCOReD 
network.  Weighted standard deviation (SDiw) and variability independent of the 
mean (VIM) derived from 24-h ambulatory blood pressure decreased  significantly 
after renal denervation. Furthermore, baseline diastolic SDiw and VIM correlated 
with blood pressure changes after renal denervation. Our results suggest that (i) 
responders to renal denervation may derive ancillary benefits from reduction in 
blood pressure variability; (ii) baseline blood pressure variability may predict blood 
pressure response to renal denervation. 
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Introduction  
Blood pressure (BP) variability is the result of complex interactions between 
extrinsic environmental and behavioral factors and intrinsic cardiovascular regulato-
ry mechanisms, both humoral and neural [1,2]. The influence of these different 
factors is difficult to disentangle. However, it is generally accepted that central sym-
pathetic drive is one of the main determinants of BP variability [1,3] and treatment-
resistant hypertension [4,5]. In particular, studies implementing microneurographic 
traffic recordings from peroneal nerves, showed a direct relation between 24-h BP 
variability and muscle sympathetic nerve activity (MSNA) [6]. We hypothesized that 
an intervention targeting to reduce renal sympathetic nerves activity, such as renal 
denervation (RDN), might decrease BP variability, which if confirmed in the long-run 
might decrease cardiovascular risk [7]. However, previous studies testing this hy-
pothesis were usually small, monocentric [2,7,8], and applied indices of BP variabil-
ity that were heavily dependent on the BP level [2,7-9]. These studies did therefore 
not allow to prove or disprove that  RDN influenced  BP variability.   None of the 
aforementioned studies tested whether BP baseline variability predicted the BP 
response to RDN over and above baseline BP. 
Furthermore, in view of the modest BP benefits of RDN performed with the 
unipolar Symplicity catheter [10,11], the identification of responders to RDN is a 
central issue in the field [12,13]. As patients with higher baseline sympathetic tone 
may respond better to RDN, the identification of an easy-to-determine, non-invasive 
8 
 
index of baseline sympathetic activity, likely to predict the BP response to RDN, is a 
top research priority [12,13].  
In this study, we took advantage of the collaboration within the European Net-
work Coordinating research on Renal Denervation (ENCOReD) [14]. We assessed 
changes in 24-hour ambulatory BP variability  in response to RDN and investigated 
whether baseline BP variability predicted the 6-month BP changes induced by RDN. 
We used ambulatory monitoring as the state-of-the-art technique for the assess-
ment of BP. 
Methods  
Patients  
Following the fifth ENCOReD network meeting, held in Leuven on 31 Janu-
ary 2014, 11 centers volunteered to contribute anonymised data for analysis.  The 
eligibility criteria for RDN at the participating centers complied with the European 
consensus [15] and have been described previously [14].  Briefly, eligibility criteria 
for RDN included: (i) optimized treatment with 3 or more antihypertensive drug clas-
ses at the maximal tolerated dose, preferably including a diuretic; (ii) a systolic 
office BP of at least 140 mmHg; (iii) a daytime or 24-h systolic BP of at least 135 or 
130 mmHg, respectively; (iv) an estimated glomerular filtration rate (eGFR) of 30 
ml/min/1.72 m2 or higher; (v) systematic exclusion of secondary hypertension; (vi) 
suitable anatomy of the renal arteries (diameter ≥ 4 mm, length ≥ 20 mm, absence 
of stenosis ≥ 50% or renal artery stent.  All patients  who underwent at least two 24-
h BP measurements of sufficient quality, one at baseline and the second at follow-
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up and in whom the unedited BP recordings could be made available were eligible 
for inclusion in this analysis.  Ambulatory BP recordings were reviewed for 222 
consecutively enrolled patients.  Of those, we excluded 52, due to missing readings 
during 3 consecutive hours on ambulatory BP monitoring, either at baseline or at 
follow-up. Three additional patients were discarded, because the number of daytime 
or nighttime readings was less than 10 or 5, respectively.  The total number of pa-
tients eligible for inclusion in the current analysis was therefore 167. All participating 
centers  received approval from the competent Institutional Review Board. Patients 
provided written informed consent except in centers where RDN is part of routine 
clinical care. 
Blood Pressure Measurement  
In the current RDN studies, office BP was measured either by validated oscillome-
tric devices (ten centers) or auscultation of the Korotkoff sounds (one center).  The 
number of office readings averaged per visit ranged from 2 to 5.  All participating 
centers used validated portable monitors to measure the ambulatory BP according 
to the guidelines of the European Society of Hypertension [16].  Across centers, the 
intervals between daytime and nighttime readings ranged from 15 to 30 minutes 
and from 30 to 60 minutes, respectively.  The recordings were sparsely edited, 
removing only readings labelled with an error code or with lower systolic than dias-
tolic BP level. We computed the daytime and nighttime BP as the within-individual 
mean of the readings between 10 AM and 8 PM (daytime) and 12 PM to 6 AM 
(nighttime) respectively, weighted for the interval between readings. These short 
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definitions of daytime and nighttime eliminate the transition periods in the morning 
and the evening during which BP changes rapidly in most people and result in day-
time and nighttime BP levels that approximate within 1-2 mmHg to the wakeful and 
asleep BP recorded by the diary method [18].    
Blood Pressure Variability   
We assessed reading-to-reading 24-hour BP variability using different estimates, 
both dependent (weighted standard deviation, average real variability) and inde-
pendent of the mean (coefficient of variation, variance independent of the mean). 
Weighted standard deviation (SDiw) is  the standard deviation (SD) over 24 hours 
weighted for the time interval between consecutive readings[19-20]  . Average real 
variability (ARV) [21] is the average of the absolute differences between consecu-
tive BP measurements. It has the advantage of accounting for the order of the BP 
measurements. Standard deviation weighted according to Bilo et al.(SDtw) [22] is 
the average of daytime and nighttime SD weighted for the duration of the daytime 
and nighttime interval. It allows to get rid of the influence of nocturnal BP fall . How-
ever, it remains dependent to some extent of mean BP. Coefficient of variation (CV) 
is SD divided by the mean. Finally, variance independent of the mean (VIM) [23] is 
calculated as the SD divided by the mean to the power x and multiplied by the 
population mean to the power x. The power x is obtained by fitting a curve through 
a plot of SD against mean using the model SD = a  x meanx, where x was derived 
by non-linear regression analysis as implemented in the PROC NLIN procedure of 
the SAS package.  
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Statistical Methods  
We used SAS, version 9.4, for database management and statistical analysis.  
We applied Student’s  t-tests to compare unadjusted means and to determine the 
significance of unadjusted within-group BP and BP variability changes (follow-up 
measurement subtracted from baseline) and the χ2 –statistic to compare propor-
tions. To estimate baseline predictors of changes in BP variability, we applied a 
generalization of the standard linear model, as implemented in the PROC MIXED 
procedure of the SAS package.  In multivariable-adjusted analyses, we considered 
as covariables: sex, age, body mass index, mean arterial pressure, pulse pressure, 
baseline night-day mean BP ratio, glomerular filtration rate (eGFR; estimated ac-
cording to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for-
mula) [24], smoking and drinking, and a history of diabetes mellitus or cardiovascu-
lar disease. In mixed models, we also adjusted for baseline and we accounted for 
center as a random effect.  Significance was a two-tailed α level of 0.05 or less. 
Results 
Baseline Characteristics   
Twenty-four hour ambulatory BP measurements were analyzed in 167 patients 
(mean age 56.7 years; 40.1% women; mean baseline office and 24-h ambulatory 
BP: 172/98 and 152/90 mmHg, respectively). The median number of ambulatory 
blood pressure readings at baseline was 58 (IQR: 45-64; 5th-95th percentile: 33-78) 
over 24 hours, 28 (IQR: 20-31; 5th-95th percentile: 16-40) during daytime and 12 
(IQR: 7-13; 5th-95th percentile: 6-18) during nighttime. Corresponding numbers at 
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follow-up were 58 (IQR: 46-65; 5th-95th percentile: 31-77) over 24 hours, 27 (IQR: 
21-30; 5th-95th percentile: 13-39) during daytime and 12 (IQR: 7-13; 5th-95th percen-
tile: 6-18) during nighttime. Table 1 lists the baseline characteristics of the patients 
across tertiles of 24-h systolic BP (<143 mmHg; 143-159 mmHg, ≥ 159 mmHg). The 
proportion of smokers was higher in the second (20.7%) and third (20.4%) tertiles 
compared to the first (3.6%) tertile of systolic BP (P=0.016). Mean age tended to be 
higher in the first (59.5 years) compared to the second (54.7 years) and third (56.1 
years) tertiles (P=0.053). 24-h ambulatory heart rate increased significantly across 
tertiles of 24-h systolic and diastolic BP (p<0.029). Otherwise, the groups did not 
differ with regard to body mass index, eGFR, prevalence of diabetes or previous 
cardiovascular diseases. SDtw and ARV derived from systolic BP slightly increased 
with higher category of 24-h systolic BP (SDtw: 13.1±4.6; 14.6±4.3; 15.2±4.4 
mmHg; P=0.041; ARV: 12.0±3.1; 13.2±4.2; 13.7±4.2mmHg; P=0.06), whereas no 
trend was observed for SDiw, CV or VIM derived from systolic BP. SDiw, SDtw  and 
ARV derived from diastolic BP significantly increased across tertiles of diastolic BP 
(SDiw: 11.6±3.6; 13.0±4.3; 14.8±4.3; P=0.0004; SDtw: 8.9±2.4; 10.2±2.8; 11.8±4.2; 
P<0.0001; ARV: 8.6±2.6; 9.6±3.1; 10.8±4.1; P=0.002 ). No trend was observed for 
CV or VIM derived from diastolic BP. Notably, after exclusion of 68 patients with 
less than 20 daytime and 7 nighttime BP readings [25], these findings remained 
virtually unchanged (data not shown). 
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Renal sympathetic denervation 
Experienced interventional specialists performed all procedures. Symplicity cathe-
ters were used in most cases (Symplicity: 72%, Symplicity Flex: 8%, Symplicity 
Spyral: 0.5%). Other catheters used were 6F short IMA catheters (13%), Vessix 
(4%), St Jude EnlighHTN (2%) and Covidien OneShot (0.5%) catheters. 
 
Experienced changes in Blood Pressure level after RDN  
The systolic/diastolic BP reductions between baseline and follow-up (6.7 ± 2.5 
months after RDN) averaged 15.4/6.6 mmHg for office BP, and 5.5/3.7 mmHg (Ta-
ble 2), 6.3/4.1 mmHg, and 4.5/2.9 mmHg for 24-h, daytime and nighttime ambulato-
ry BP, respectively (P<0.001 for all).  The 24-h ambulatory heart rate decreased 
from baseline to follow-up with -1.12 (95%CI: -2.17 to -0.08) beats per minute (p= 
0.035 after multivariable adjustment). The number of drug classes decreased from 
4.8±1.5 at baseline to 4.3±1.7 at follow-up (P<0.001).   
Changes in Blood Pressure variability after RDN  
Changes in ARV derived from systolic or diastolic 24-h ambulatory BP did not reach 
statistical significance (-0.20, P=0.49; -0.31, P=0.29, respectively). Similarly, de-
creases in CV were not significant (-0.45, P=0.12; -0.39, P=0.28, for 24-h systolic 
and diastolic BP, respectively).  SDiw, SDtw  and VIM derived from 24-h systolic BP 
decreased by -1.29 mmHg (95%CI: -2.17 to -0.42; P=0.004), -0.78 mmHg (95%CI: -
-1.43 to -0.12; P=0.02) and -1.11 mmHg (95%CI: -1.92 to -0.30; P=0.007), respec-
tively. Decreases in SDiw and VIM derived from systolic BP (-1.18 mmHg, 95%CI: -
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1.84 to -0.51; P=0.0006 and -0.86 mmHg, 95%CI: -1.45 to -0.27; P=0.005, respec-
tively) remained significant in multivariable-adjusted analyses   and were paralleled 
by similar changes for 24-h diastolic BP (-0.63 mmHg, 95%CI: -1.12 to -0.13;  
P=0.014 and -0.42 mmHg, 95%CI: -0.86 to -0.01; P=0.054, respectively) (Table 2).  
 
Relation between Baseline BP Variability and Ambulatory BP Changes after RDN 
We also tested the relations of BP variability indices at baseline with changes in 
ambulatory BP level after RDN, expressed as the difference of 24-ambulatory BP at 
baseline minus follow-up  (6.7±2.5 months after RDN).While the relation between 
baseline SDw derived from 24-ambulatory systolic BP and change in 24-h systolic 
ambulatory BP after RDN was borderline significant (P=0.057), no relation was 
found between other BP variability estimates at baseline and 24-h ambulatory sys-
tolic BP response to RDN (P=0.35, 0.97 and 0.25, for baseline ARV, CV and VIM, 
respectively). In contrast, baseline SDiw (P=0.0006), ARV (P=0.01) and VIM 
(P=0.04) - but not CV (P=0.22) - derived from 24-h diastolic BP were significantly 
related with changes in 24-h diastolic BP level after RDN. After adjustment for base-
line BP, correlations with SDiw (P=0.028) and VIM (P=0.030) - but not ARV 
(P=0.17) - remained statistically significant, while the correlation with CV reached 
statistical significance (P=0.031) (Figure 1). Finally, we attempted to determine the 
optimal threshold value of the different BP variability estimates for predicting diastol-
ic BP decrease after RDN. Diastolic BP response was defined as a mean 24-hour 
diastolic BP change > 10 mmHg after RDN. Thresholds were determined by maxim-
izing the Youden index (maximum of sensitivity plus specificity minus 1).  The opti-
15 
 
mal thresholds for each baseline variability estimate, the proportion of patients 
correctly or incorrectly classified as responders or non-responders, as well as the 
corresponding sensitivity, specificity and predictive values are indicated in Table 3. 
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Discussion  
The two key findings of this new analysis of the ENCOReD database are the 
following: (i) RDN decreases not only BP level, but BP variability as well; (ii) diastol-
ic BP variability at baseline is correlated with 24-h diastolic BP changes in response 
to RDN.  
Several studies [2,7-9]  proposed that RDN might decrease BP variability, as 
captured by the unadjusted [2,7-9] or adjusted [2] standard deviation of mean 24-h 
ambulatory BP,  time-rate of 24-h ambulatory BP variation (mean of the absolute 
ratios of the difference between successive BPs and the minutes between them) 
[8], ARV [2,9] and CV of 24-h ambulatory BP [2,9]. However, most of these anal-
yses [2,7,8] were performed in small, single centre cohorts (sample sizes ranging 
from 11 to 31). The effect of RDN on the indices of BP variability was not always 
consistent between studies, and some of the indices chosen, such as unadjusted 
standard deviation of the mean or ARV, are strongly related with mean BP [26]. In 
all studies [2,7,9] but one [8], RDN was performed using the Symplicity unipolar 
catheter. Finally, none of these studies assessed VIM, which is considered to be a 
particularly robust index of BP variability independent of the mean [23].  
In contrast with the publication by Miroslawska et al. [2], performed in a small 
subset (n=23) of truly adherent patients with resistant hypertension, in the EN-
COReD database, RDN was not followed by a significant decrease in ARV  or CV. 
Notably however, in the recent study by Ewen et al. [9] including 84 patients, 
changes in these measurements were only borderline significant 6 months after 
RDN (P=0.054 and 0.071, respectively). We nevertheless documented a significant 
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decrease in VIM of 24-h systolic  and diastolic BP. The decrease in VIM of 24-h 
systolic - but not diastolic - BP remained significant in a fully adjusted model (Table 
2). While most BP variability indices, including CV [23] may be influenced by mean 
BP values, VIM includes an additional coefficient derived from curve fitting which 
makes it truly independent of the mean [23,26].  Along the same lines, standard 
deviation weighted according to Bilo et al.(SDtw) [22], which allows to get rid of the 
influence of nocturnal BP fall, also decreased after RDN, though significance was 
lost after full adjustment . However, it remains dependent to some extent of mean 
BP. Overall, our results strongly suggest that RDN decreases BP variability over 
and above its effect on BP level.  The lack of decrease in visit-to-visit VIM in the 
Syst-Eur randomised controlled trial in the placebo and active-treatment arms [27] 
further supports the hypothesis that decreased BP variability documented after 
RDN is not entirely explained by reduction of BP level or regression to the mean, 
but at least partly reflects the sympatholytic effects of the intervention per se [1,3]. 
Besides a decrease in BP and BP variability, RDN was also associated with a de-
crease in heart rate. These findings are not unexpected in view of the influence of 
sympathetic system on heart rate and are in agreement with previous studies 
[28,29].  
Whether decreased BP variability after RDN may contribute to improve cardio-
vascular prognosis over and above mean BP decrease remains to be demonstrat-
ed. First, the possible benefits of RDN in terms of “hard” cardiovascular endpoints 
remain unsubstantiated. Second, both changes in BP level [14] and BP variability 
after RDN using the Symplicity system are modest and highly variable among indi-
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vidual patients. Last but not least, most studies have been performed using BP 
variability indices that are highly correlated with mean BP [26]. VIM was used in few 
studies, mostly to assess visit-to-visit BP variability rather than 24-h ambulatory BP 
variability as in the present study. In the ASCOT study, Rothwell et al. [23] found a 
strong relation between VIM derived from office BP (visit-to-visit  BP variability) - but 
not ambulatory BP - and cardio- and cerebrovascular events.  In contrast, in multi-
variable-adjusted analyses, BP variability indices including VIM were not independ-
ent predictors of cardiovascular morbidity or mortality, either in the Syst-Eur ran-
domized controlled trial [27] or in a population-based sample representative of the 
general Flemish population [30].  
Another key finding of our study is that baseline diastolic SDiw, ARV and VIM 
correlated with diastolic - but not systolic -BP response to RDN (Figure 2). From a 
pathophysiologic perspective, these results are meaningful. Indeed, the steady 
component of BP reflected by mean or diastolic BP is a measure of peripheral vas-
cular resistance [31], which in its turn is dependent on sympathetic tone [32] and 
decreases after renal sympathetic nerve ablation [33]. Several lines of evidence 
suggest that increased vascular resistance, a hallmark of diastolic hypertension in 
young patients with sympathetic overactivity [34] is due to narrowing of pre-capillary 
arterioles, and that these changes precede BP elevation [35]. In contrast, systolic 
BP and pulse pressure predominantly reflect the degree of stiffness of conductance 
vessels [36], increase with the accumulation of aged-related structural damage and  
are less likely to be influenced by the autonomic system. This may explain the lack 
of predictive value of baseline systolic BP variability on systolic BP changes after 
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RDN, and more generally the modest BP-lowering effects of RDN in patients with 
isolated systolic hypertension [37]. Along the same lines, it is worth noting that in 
the recent randomized controlled study DENERVHTA comparing the BP lowering 
efficacy of  RDN with that of 50 mg of spironolactone in patients with resistant hy-
pertension, the decrease in BP variability was limited to the RDN arm and signifi-
cant only for diastolic - not systolic - BP [38]. Notably, the BP reduction associated 
with RDN  precedes and seems to be independent of decrease in sympathetic 
nerve system activity assessed by MSNA [39]. Hence, the larger BP decrease ob-
served after RDN in patients with a higher baseline BP variability - and possibly a 
higher baseline sympathetic activity - may not be due to a larger decrease in sym-
pathetic nerve system activity. Our results are partly consistent with those obtained 
by Tsioufis  et al. [8] in a cohort of 31 patients denervated using the EnligHTN multi-
electrode ablation catheter.  Nevertheless, comparison is difficult, as the latter used 
a different BP variability estimate, namely time rate, defined as the first derivative of 
the BP values against time (mean of the absolute ratios of the differences between 
successive BPs and the minutes between them). 
Our study should be interpreted within the context of its limitations. The most 
important is the absence of control group, which makes it vulnerable to the Haw-
thorne effect and other patient-and physician-related bias [40]. However, this limita-
tion is mitigated by the use of BP variability estimates derived from 24-hour ambula-
tory blood pressure variability, which is blinded by definition, rather than visit-to-visit 
BP variability,  and inclusion of  VIM, which is independent of BP level, and may 
thus be even less influenced by placebo and white-coat effects. Second, most pa-
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tients (>80%) were denervated using the first-generation unipolar Symplicity cathe-
ter. Hence, our results cannot be extrapolated to more performant, second-
generation catheters, which might produce more efficient RDN and therefore larger 
effects on BP variability.  Third, in the absence of procedural endpoint [41], the 
completeness of RDN could not be assessed. Finally, while the number of pre-
scribed antihypertensive drug classes was documented both at baseline and 6 
months after RDN, details on medications and posology were not systematically 
recorded, and drug adherence was not assessed in most centers [14]. In the ab-
sence of the confounding effect of drugs change, the predictive value of baseline 
BP variability on BP response to RDN may be even better. Still, with 167 patients 
from 11 European centers, our study is the largest performed on BP variability up to 
now. The mean 24-h BP decrease after RDN (-5 mmHg) is similar to that observed 
in our initial ENCOReD patient level meta-analysis [14] and in the highly standard-
ized DENERHTN randomised controlled trial [42]. Finally, this study is the first to 
assess BP variability independent of the mean (VIM), and to look for the predictive 
value of baseline BP variability on BP outcome after RDN.  
In conclusion, RDN using the unipolar Symplicity catheter was associated with a 
decrease in short-term BP variability at 6 months, over and above a modest de-
crease in BP level. Whether this would translate into additional benefits in terms of 
cardiovascular mortality and morbidity remains to be proven. Furthermore, baseline 
BP variability estimates were related with diastolic BP changes after RDN. This 
intriguing observation needs confirmation in randomized controlled studies using 
more efficient and reproducible RDN systems, and/or RDN guided by renal nerve 
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stimulation [39], including younger, ideally untreated patients with milder hyperten-
sion, a group considered as particularly suitable for upcoming RDN trials [11,13].  
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Table 1 Baseline characteristics of 167 patients across tertiles of 24-h systolic or diastolic BP level 
Baseline characteristics 24-h systolic BP  24-h diastolic BP 
 ≤142 mmHg 143-158 mmHg ≥159 mmHg P-value  ≤83 mmHg 84-95 mmHg ≥96 mmHg P-value 
Number (%) with characteristic  55 58 54   54 56 57  
Women  19 (34.6) 20 (34.5) 28 (51.9) 0.10  19 (35.2) 22 (39.3) 26 (45.6) 0.53 
Non-white ethnicity  1 (1.8) 1 (1.7) 4 (7.4) 0.19  0 (0) 2 (3.6) 4 (7.0) 0.14 
Smokers  2 (3.6) 12 (20.7)‡ 11 (20.4) 0.016  3 (5.6) 5 (8.9) 17 (29.8)† 0.0005 
Drinking alcohol  25 (45.5) 22 (37.9) 14 (25.9) 0.10  25 (46.3) 20 (35.7) 16 (28.1) 0.14 
Diabetes mellitus  17 (30.9) 11 (19.0) 18 (33.3) 0.19  23 (42.6) 15 (26.8) 8 (14.0) 0.003 
Previous cardiovascular disease           
Coronary heart disease  8 (14.6) 11 (19.0) 9 (16.7) 0.82  13 (24.1) 8 (14.3) 7 (12.3) 0.21 
Stroke  2 (3.6) 4 (6.9) 4 (7.4)* 0.66  3 (5.6) 3 (5.4) 4 (7.0) 0.92 
Mean (SD) characteristic           
Age, y  59.5±11.6 54.7±9.6* 56.1±10.8 0.053  64.2±9.6 54.9±9.5‡ 51.3±9.2* <0.0001 
Body mass index, kg/m2   29.6±4.8 30.0±5.3 30.2±5.7 0.83  30.4±5.2 29.8±5.4 29.7±5.3 0.73 
Serum creatinine, µmol/L  88.2±21.8 85.1±28.8* 84.3±25.2 0.70  86.2±19.5 87.3±29.8 84.2±25.9 0.81 
eGFR, ml/min/1.73 m2  78.8±18.0 84.2±19.7 82.0±19.5 0.33  76.4±16.9 82.3±19.6 86.2±19.7 0.025 
24-hour ambulatory heart rate 67.5±10.9 70.5±10.2 72.8±9.7 0.029  65.4±9.4 70.8±10.5† 74.3±9.6 <0.0001 
Office blood pressure           
Systolic BP, mmHg  159.9±19.1 171.6±30.1* 184.1±25.3* <0.0001  167.9±26.3 168.1±24.6 179.1±28.9* 0.04 
Diastolic BP, mmHg  91.9±11.4 98.3±18.1* 102.4±18.2 0.004  85.5±11.1 96.6±12.3‡ 109.9±15.5‡ <0.0001 
Blood pressure variability (SBP)           
SDiw, mm Hg 17.1±6.2 18.0±5.0 19.4±5.7 0.099  17.5±5.9 17.8±5.7 19.2±5.4 0.26 
SDtw, mm Hg 13.1±4.6 14.6±4.3 15.2±4.4 0.041  13.3±3.9 14.1±4.7 15.4±4.7 0.045 
ARV, mm Hg 12.0±3.1 13.2±4.2 13.7±4.2 0.060  12.6±3.9 12.4±3.5 13.8±4.3 0.12 
CV, % 12.8±4.6 11.9±3.2 11.4±3.4 0.15  12.4±4.0 12.0±4.0 11.8±3.4 0.74 
VIM, units 17.8±6.3 17.5±4.6 17.6±5.0 0.97  17.4±5.4 17.4±5.5 18.1±5.1 0.75 
Blood pressure variability (DBP)           
SDiw, mm Hg 12.6±4.4 13.2±4.0 13.7±4.3 0.38  11.6±3.6 13.0±4.3 14.8±4.3* 0.0004 
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SDtw, mm Hg 9.5±3.1 10.5±3.9 11.0±3.2 0.066  8.9±2.4 10.2±2.8* 11.8±4.2* <0.0001 
ARV, mm Hg 9.1±3.2 9.6±3.7 10.3±3.3 0.066  8.6±2.6 9.6±3.1 10.8±4.1 0.002 
CV, % 15.8±5.5 14.6±4.1 14.1±4.4 0.16  15.7±5.2 14.5±4.7 14.2±4.3 0.23 
VIM, units 13.1±4.5 12.8±3.6 12.5±3.3 0.15  12.7±4.0 12.5±3.7 13.1±3.9 0.71 
eGFR: glomerular filtration rate estimated from the serum creatinine concentration using CKD-EPI formula.  P-values denote significance of the differences in prevalence rates 
or means across tertiles of 24-h systolic (SBP) or diastolic (DBP) blood pressure. SDiw: standard deviation over time weighted for the time interval between consecutive 
readings.  SDtw:  average of daytime and nighttime standard deviation weighted for the duration of the daytime and nighttime interval.  ARV: average real variability. CV: 
coefficient of variation. VIM: variability independent of mean. Significance of the difference with the adjacent lower tertile: * P≤0.05; † P≤0.01; ‡ P≤0.001.
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Table 2  
Baseline values and 6-month changes (∆) in 24-h BP level and variability indices 
BP level and  
variability 
24-h systolic  
Ambulatory BP 
P-value  
24-h diastolic  
Ambulatory BP  
P-value 
24-h BP level, 
mm Hg      
Baseline  151.6±16.8   89.6±13.4  
Unadjusted ∆  -5.48 (-8.12 to -2.85) <0.0001  -3.72 (-5.38 to -2.07)‡ <0.0001 
Adjusted ∆ -5.18 (-7.41 to -2.94) <0.0001  -3.84 (-5.21 to -2.47) <0.0001 
      
SDiw, mm Hg      
Baseline 18.2±5.7   13.2±4.3  
Unadjusted ∆  -1.29 (-2.17 to -0.42) 0.004  -0.89 (-1.58 to -0.21) 0.011 
Adjusted ∆ -1.18 (-1.84 to -0.51) 0.0006  -0.63 (-1.12 to -0.13) 0.014 
SDtw, mm Hg      
Baseline 14.3±4.5   10.3±3.5  
Unadjusted ∆  -0.78 (-1.43 to -0.12) 0.020  -0.53 (-1.07 to 0.01) 0.055 
Adjusted ∆ -0.43 (-0.92 to 0.06) 0.087  -0.22 (-0.64 to 0.20) 0.30 
ARV, mm Hg      
Baseline 12.9±4.0   9.7±3.4  
Unadjusted ∆  -0.20 (-0.78 to 0.38) 0.49  -0.31 (-0.87 to 0.26) 0.29 
Adjusted ∆ -0.38 (-0.77 to 0.01) 0.059  0.01 (-0.35 to 0.38) 0.94 
      
CV, %      
Baseline 12.0±3.8   14.8±4.7  
Unadjusted ∆ -0.45 (-1.0 to 0.12) 0.12  -0.39 (-1.10 to 0.32) 0.28 
Adjusted ∆ -0.51 (-0.94 to -0.08) 0.020  -0.37 (-0.92 to 0.18) 0.18 
VIM, units      
Baseline 17.6±5.3   12.8±3.8  
Unadjusted ∆  -1.11 (-1.92 to -0.30) 0.007  -0.77 (-1.36 to -0.18) 0.011 
Adjusted ∆ -0.86 (-1.45 to -0.27) 0.005  -0.42 (-0.86 to -0.01) 0.054 
SDiw: standard deviation over time weighted for the time interval between consecutive readings. SDtw:  
average of daytime and nighttime standard deviation weighted for the duration of the daytime and nighttime 
interval.   ARV: average real variability. CV: coefficient of variation. VIM: variability independent of mean. 
Changes are follow-up – baseline.
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Table 3 Classification of 24-h diastolic BP level changes after RDN (∆) by baseline BP variability indices 
Blood pressure 
variability indices  
(threshold*) 
 Correctly classified  Incorrectly classified  Classification parameters 
 Responder Non-responder  Responder 
Non-
responder  
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
SDiw 
(11.8 mm Hg)  28 66  65 8  77.8 50.4 30.1 89.2 
SDtw 
(8.7 mm Hg)  30 59  72 6  83.3 45.0 29.4 90.8 
ARV 
(7.8 mm Hg)  30 55  76 6  83.3 42.0 28.3 90.2 
CV 
(15.0%)  18 83  48 18  50.0 63.4 27.3 82.2 
VIM 
(13.5 units)  17 94  37 19  47.2 71.8 31.5 83.2 
* Optimal threshold values of the different BP variability indices for predicting diastolic BP changes after RDN were determined by maximizing the Youden index.  Responder: 
mean 24-h diastolic BP decrease > 10 mm Hg after RDN (follow-up - baseline).  Non-responder: mean 24-h diastolic BP decrease ≤ 10 mm Hg. SDiw: standard deviation 
over time weighted for the time interval between consecutive readings.  SDtw: average of daytime and nighttime standard deviation weighted for the duration of the daytime 
and nighttime interval.  ARV: average real variability.  CV: coefficient of variation.  VIM: variability independent of mean.   
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Legends of the Figures: 
Figure 1: relation between baseline BP variability indices dependent (SDiw, ARV) 
and independent (CV, VIM) of the mean derived from 24-h diastolic BP (X-axis) 
and baseline-adjusted changes in 24-h diastolic BP after RDN (Δba 24-h DBP) 
(Y-axis). BP: blood pressure. The dotted lines on both sides of  the regression line 
represent the 95% confidence interval. 
 
